New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
11:10 EDTFURX, TKPYYFuriex confirms Takeda to present additional EXAMINE trial data
Furiex Pharmaceuticals (FURX) confirmed that its partner Takeda Pharmaceuticals (TKPYY) will present sub-analyses from the global EXAMINE, EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome, cardiovascular safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session. These sub-analyses specifically relate to the effects of alogliptin on rates of CV mortality and hospitalization for heart failure, Furiex said. Findings from one sub-analysis demonstrated no effect on rates of CV mortality. There was also no increase in sudden cardiac death with alogliptin. The other sub-analysis demonstrated that in patients with Type 2 diabetes and recent ACS, the pre-specified composite CV outcome of first occurrence of all-cause mortality, nonfatal myocardial infarction and stroke, urgent revascularization due to unstable angina, and hospitalization for heart failure was similar for alogliptin compared with placebo.
News For FURX;TKPYY From The Last 14 Days
Check below for free stories on FURX;TKPYY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:31 EDTTKPYYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 11, 2014
06:49 EDTTKPYYFDA approves weight management drug Contrave
The U.S. Food and Drug Administration yesterday approved Contrave as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index of 30 or greater or adults with a BMI of 27 or greater who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation. The effectiveness of Contrave was evaluated in multiple clinical trials that included approximately 4,500 obese and overweight patients with and without significant weight-related conditions treated for one year. Contrave is distributed by Takeda Pharmaceuticals America (TKPYY) for Orexigen Therapeutics (OREX).
September 8, 2014
17:22 EDTTKPYYOrexigen, Takeda Pharmaceutical in services agreement
Orexigen disclosed in a regulatory filing that in preparation for the potential launch of NB32, Orexigen Therapeutics (OREX) and Takeda Pharmaceutical Company (TKPYY) entered into a Manufacturing Services Agreement, dated September 2, in accordance with the Collaboration Agreement between the company and Takeda, effective as of September 1, 2010, as amended by Amendment Number 1 to Collaboration Agreement effective as of September 26, 2013. Pursuant to the Agreement, among other things, the company will supply to Takeda, and Takeda will, subject to certain exceptions as set forth in the Agreement and Collaboration Agreement, exclusively purchase from the Company, all of Takeda’s requirements of NB32 for commercialization in the United States, Canada and Mexico during the term of the Collaboration Agreement. The Agreement will continue in full force and effect until the expiration or termination of the Collaboration Agreement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use